研究针对针对MDM2/MDMX的抗瘤主干的设计,合成和活性
Jian Yang1, Xiufei Liao2, Damin Hu2
1The Third Affiliated Hospital of Chengdu Medical College (Chengdu Pidu District People's Hospital), Chengdu, China.
Frontiers in chemistry
|June 24, 2024
概括
主要提供了改善的药物特性,如抗分解. 在实验室研究中,一种新的双向,SM3-4有效诱导瘤细胞死亡.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 主要体表现出增强的药理特征,包括蛋白质分解抵抗和细胞透.
- 双重向质通过抑制多个瘤性途径,为癌症治疗提供了一个有希望的策略.
研究的目的:
- 设计和合成新的双重向MDM2/MDMX主干.
- 为了评估这些的抗瘤活性,与它们的直链对应物相比.
主要方法:
- 基于PMI-M3的双重向MDM2/MDMX主干的合成.
- 瘤细胞亡诱导的体外评估.
- 对二次结构的分析,特别是螺旋性.
主要成果:
- 主要酸SM3-4在低微分子度下显著诱导瘤细胞亡.
- 与直链类似物相比,SM3-4的螺旋性增加了.
- 增强的螺旋性与改善的抗瘤活性相关.
结论:
- SM3-4是一种强大的双重向主干,具有显著的抗瘤潜力.
- 增加的螺旋性是促进主质的增强活性的一个关键因素.
- 这些发现为开发基于主食的新型抗癌疗法提供了基础.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
